How GLP1 receptor drugs and related treatments may help certain obesity-related health problems and why they should be prioritized

Compliance with Ethical Standards. Competing Interest: Conflicts of interest/Competing interests Funding: JM has received research funding from the NIHR and the Society for Endocrinology. JM has received institutional funding form NovoNordisk and Rhythm Pharmaceuticals. JS is supported by the NIHR Oxford Biomedical Research Centre (NIHR203311) and is an investigator in a trial funded by the Novo Nordisk Foundation (NNF22SA0080921). IS has received research grants or Speaker fees from: Eli Lilly, Novo Nordisk, Abbott, Boehringer, Sanofi. PSG has received speaker & course director fees from Novo Nordisk, advisory/speaker fees from Eli Lilly, and research support from Recordari. BM has received educational and/or advisory fees Lilly, Novonordisk, Boheringer ingelheim, Astra Zeneca. BM has received a research grant from Novo Nordisk. CA has received reimbursement for attending conferences from Novo Nordisk. Financial interests: TT declares she is a former shareholder in, and consultant for Zihipp Ltd., as well as advisory board consultancies for Amylyx Inc. Non-financial interests: JM has a voluntary role with the Asociation for the Study of Obesity (ASO) as sponsorship lead. BM is a shareholder of Reset Health. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.